These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18927307)

  • 1. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
    Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
    Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.
    Gao K; Lockwood WW; Li J; Lam W; Li G
    Int J Oncol; 2008 Jun; 32(6):1343-9. PubMed ID: 18497997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
    Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
    de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
    Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
    Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
    Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
    Ikai A; Watanabe M; Sowa Y; Kishimoto M; Yanagisawa A; Fujiwara H; Otsuji E; Sakai T
    Int J Oncol; 2016 Mar; 48(3):1297-304. PubMed ID: 26783196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
    Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
    Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
    Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
    Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
    Matsuyama R; Togo S; Shimizu D; Momiyama N; Ishikawa T; Ichikawa Y; Endo I; Kunisaki C; Suzuki H; Hayasizaki Y; Shimada H
    Int J Cancer; 2006 Jul; 119(2):406-13. PubMed ID: 16477629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.